Printer Friendly

NEORX ANNOUNCES ENHANCED TUMOR DOSE FROM PRE-TARGETING IN PRECLINICAL MODELS

 NEORX ANNOUNCES ENHANCED TUMOR DOSE FROM PRE-TARGETING IN
 PRECLINICAL MODELS
 LOS ANGELES, Calif., June 11 /PRNewswire/ -- NeoRx Corporation (NASDAQ: NERX) today presented data at the Society of Nuclear Medicine Conference here on its rhenium-186 targeted radiotherapy that showed that the company's patented technique doubled the dose of radiation delivered to tumors and, simultaneously, nearly halved the amount of radiation in the blood that causes bone marrow toxicity. The cumulative impact, comparing tumor to marrow, is a nearly 300 percent improvement in the therapeutic index, the difference between dose to tumor and dose to normal organs.
 "These preclinical results demonstrate that NeoRx's pre-targeting technology can improve the therapeutic index in a dramatic fashion," said John M. Reno, director, research and product development. "We have postulated that the use of this technology may allow a major advance in the treatment of cancer. We continue to improve the technology, with the goal of achieving a ten-fold increase in the therapeutic index. We plan to have this new technology in clinical trials in less than a year," continued Reno.
 NeoRx Corporation develops targeted biopharmaceutical products that detect and treat human illnesses with a primary focus on cancer. The company has three cancer therapy trials in progress, has filed for marketing approval with the Food and Drug Administration for two OncoTrac(R) cancer imaging products, and has completed a Phase III trial for a third imaging product. Targeted biopharmaceuticals to treat cancer, restenosis after angioplasty, and autoimmune diseases are in pre-clinical testing.
 -0- 6/11/92
 /CONTACT: Robert M. Littauer, vice president, chief financial officer and treasurer of NeoRx, 206-286-2519; or Anthony J. Russo or Susan A. Noonan of Noonan/Russo Communications, 212-979-9180, for NeoRx/
 (NERX) CO: NeoRx Corporation ST: California IN: MTC SU:


TQ-GK -- NY012 -- 9099 06/11/92 09:03 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 11, 1992
Words:298
Previous Article:PAULSON CAPITAL ANNOUNCES MANAGEMENT CHANGES FOR ITS OPERATING SUBSIDIARY
Next Article:BET HOLDINGS, INC. REPORTS THIRD QUARTER RESULTS
Topics:


Related Articles
NEORX DEMONSTRATES EFFICACY IN ANIMALS OF TWO THERAPEUTIC PRODUCT LINES
NEORX SCIENTISTS ACHIEVE 1,000 PERCENT IMPROVED DELIVERY OF RADIOTHERAPY TO TUMORS IN ANIMAL STUDIES
NEORX CORPORATION $16 MILLION SECONDARY PUBLIC OFFERING; COMPANY REVERSE SPLITS STOCK 1 FOR 4
NEORX REPORTS PROMISING EARLY RESULTS IN AVICIDIN CANCER THERAPY STUDIES
A SINGLE DOSE OF NEORX'S AVICIDIN PRODUCES CURES IN PRECLINICAL ANIMAL MODELS
NEORX'S AVICIDIN ADVANCES IN PHASE I II CANCER THERAPY TRIALS
A SINGLE DOSE OF NEORX'S AVICIDIN PRODUCES TUMOR REGRESSIONS IN EARLY PHASE I TRIALS; DOSE OPTIMIZATION AND ESCALATION TO CONTINUE
NeoRx Updates Progress on Verluma(TM), Avidicin(TM) and Biostent(TM)
NeoRx Receives Japanese Pretargeting Patent; US and European Patents Previously Issued

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters